EUVIMEDObjevte EUVIMED
Systematische ÜbersichtMetaanalyse

Botulinum toxin A for the treatment of neurogenic bladder in children: a systematic review and meta‐analysis

Botulinumtoxin A zur Behandlung der neurogenen Blase bei Kindern: systematische Übersicht und Metaanalyse

Guorong He, Nan Shen, Shaoguang Feng iD

ANZ Journal of Surgery · 2025-06 · 95 (6) · 1115-1121

DOI: 10.1111/ans.19309 ↗

Auf einen Blick

Die Übersicht zu intradetrusoralen BTX-A-Injektionen bei Kindern mit neurogener Blase fand Verbesserungen bei Zystometriekapazität, Detrusordruck und Blasencompliance. Die Evidenzbasis war überwiegend schwach.

Fragestellung

Wie wirksam sind intradetrusorale BTX-A-Injektionen bei Kindern mit neurogener Blase, die auf Antimuskarinika nicht ansprechen?

Methode

Systematische Übersicht und Metaanalyse nach PRISMA; Suche in PubMed, Medline und Embase nach Studien mit Originaldaten zu BTX-A bei pädiatrischer neurogener Blase.

Ergebnisse

19 Studien (1 RCT, 6 prospektive, 12 retrospektive). Maximale Zystometriekapazität +97,7 mL (95 %-KI 59,6–135,8), maximaler Detrusordruck −25,2 cm H2O (95 %-KI −39,7 bis −10,7), Blasencompliance +5,3 mL/cm H2O (95 %-KI 2,9–7,8).

Einschränkungen

Keine Studie verglich BTX-A mit Placebo; die meisten Studien hatten keine Kontrollgruppe. Die Schlussfolgerung stützt sich nicht auf Studien mit hohem Evidenzniveau.

Schlussfolgerung der Autor:innen

Intradetrusorales BTX-A erhöht bei Kindern mit neurogener Blase Zystometriekapazität, Compliance und maximale neurogene Detrusorüberaktivität. Die Autor:innen betonen jedoch die fehlende Unterstützung durch hochwertige Studien.

Kernaussagen

  • 19 Studien zu BTX-A bei pädiatrischer neurogener Blase
  • Zystometriekapazität, Detrusordruck und Compliance verbesserten sich
  • Keine Placebo-Studien; meist keine Kontrollgruppe

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

At a glance

Systematische Übersicht in ANZ Journal of Surgery, published online on 2024-11-11. Written by Guorong He and 2 co-authors. Institution: Department of Pediatrics Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China. Major MEDLINE topics: Botulinum Toxins, Type A, Urinary Bladder, Neurogenic, Neuromuscular Agents. Cited 5 times so far (Crossref); 34 references.

Auf einen BlickAbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Purpose

We performed a systematic review and meta‐analysis to assess the current evidence on the effectiveness of botulinum toxin A (BTX‐A) intradetrusor injections in paediatric NB patients who are resistant to antimuscarinic treatments.

Methods

A study was carried out on PubMed, Medline, and Embase with the search terms: (‘neurogenic bladder’ OR ‘myelomeningocele’) AND ‘toxin’ AND (‘children’ OR ‘paediatric’). The PICOS framework guided the search strategy and selection of studies in line with the PRISMA guidelines. Research involving original data that examined BTX‐A in paediatric patients with NB was included. Studies were independently chosen and data were extracted by two reviewers.

Results

Nineteen studies (one randomized controlled trial, six prospective studies, and 12 retrospective studies) that investigated the clinical application of BTX‐A injections in children with NB were identified. None of the studies compared BTX‐A to a placebo, and most lacked a control group. Results showed that maximal cystometric capacity increased by an average of 97.7 mL (34.1–162% increase) (95% confidence interval [CI] 59.6 to 135.8), while maximal detrusor pressure decreased by 25.2 cm H 2 O (95% CI −39.7 to −10.7). Bladder compliance improved by 5.3 mL/cm H 2 O (95% CI 2.9 to 7.8). After treatment, the average incontinence resolution rate among patients was 73.4%. Urinary tract infections were reported by 77 patients (13.6%).

Conclusions

BTX‐A administered intradetrusorally enhances cystometric capacity, compliance, and maximum neurogenic detrusor overactivity in paediatric patients suffering from neurogenic bladder. Nonetheless, this conclusion lacks support from studies with a high level of evidence.

Subjects

MeSH terms (MEDLINE)

Botulinum Toxins, Type AUrinary Bladder, NeurogenicNeuromuscular AgentsHumansChildTreatment Outcome

Author keywords

botulinum toxindetrusor overactivitymeta‐analysismyelomeningoceleneurogenic bladder

Substances

Botulinum Toxins, Type ANeuromuscular Agents

Authors and institutions

  • Department of Pediatrics Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.
  • Department of Pediatrics, Suqian Hospital Affiliated to Xuzhou Medical University, Suqian, Jiangsu, 223800, People's Republic of China.
  • Department of Pediatric Surgery, Hangzhou Children's Hospital, Hangzhou, Zhejiang, China.

ORCID profiles: Shaoguang Feng

Cite

APA

He, G., Shen, N., & Feng, S. (2025). Botulinum toxin A for the treatment of neurogenic bladder in children: a systematic review and meta‐analysis. ANZ Journal of Surgery, 95(6), 1115-1121. https://doi.org/10.1111/ans.19309

Vancouver

He G, Shen N, Feng S. Botulinum toxin A for the treatment of neurogenic bladder in children: a systematic review and meta‐analysis. ANZ Journal of Surgery. 2025;95(6):1115-1121. doi:10.1111/ans.19309

BibTeX
@article{He2025,
  author = {He, Guorong and Shen, Nan and Feng, Shaoguang},
  title = {Botulinum toxin A for the treatment of neurogenic bladder in children: a systematic review and meta‐analysis},
  journal = {ANZ Journal of Surgery},
  year = {2025},
  volume = {95},
  number = {6},
  pages = {1115--1121},
  doi = {10.1111/ans.19309}
}
Start for free →